These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25633268)

  • 1. Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study.
    Hoseini SM; Kalantari A; Afarideh M; Noshad S; Behdadnia A; Nakhjavani M; Esteghamati A
    Metabolism; 2015 Apr; 64(4):527-38. PubMed ID: 25633268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
    Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammations mediators and circulating levels of matrix metalloproteinases: Biomarkers of diabetes in Tunisians metabolic syndrome patients.
    Zayani Y; El Golli N; Zidi W; Guizani I; Boussairi S; Aloui S; Ayadi I; Ftouhi B; Feki M; Ben Romdhane N; Ben Sliman H; Allal-Elasmi M; Kaabachi N
    Cytokine; 2016 Oct; 86():47-52. PubMed ID: 27455450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tissue-degrading proteinases and incident cardiovascular disease events.
    Tuomainen AM; Kormi I; Havulinna AS; Tervahartiala T; Salomaa V; Sorsa T; Pussinen PJ
    Eur J Prev Cardiol; 2014 Jul; 21(7):806-12. PubMed ID: 23079500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.
    Hopps E; Lo Presti R; Montana M; Noto D; Averna MR; Caimi G
    J Investig Med; 2013 Aug; 61(6):978-83. PubMed ID: 23661104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease.
    Cicero AF; Derosa G; Manca M; Bove M; Borghi C; Gaddi AV
    Endothelium; 2007; 14(4-5):193-8. PubMed ID: 17922335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Halvorsen B; Ose L; Aukrust P; Holven KB
    Cytokine; 2013 Jan; 61(1):194-8. PubMed ID: 23131422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
    Pawlak K; Pawlak D; Mysliwiec M
    Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors.
    Tedeschi A; Asero R; Lorini M; Marzano AV; Cugno M
    Clin Exp Allergy; 2010 Jun; 40(6):875-81. PubMed ID: 20214668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein, matrix-metalloproteinase-8 and carotid atherosclerosis in spinal cord injured subjects.
    Paim LR; Schreiber R; Matos-Souza JR; Silva AA; Campos LF; Azevedo ER; Alonso K; de Rossi G; Etchebehere M; Gorla JI; Cliquet A; Nadruz W
    Atherosclerosis; 2013 Dec; 231(2):341-5. PubMed ID: 24267248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
    Głowińska-Olszewska B; Urban M
    Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.